迷走神經刺激市場規模、佔有率和成長分析（按產品類型、應用、生物材料、最終用戶和地區分類）—產業預測，2026-2033年

預計到 2024 年，迷走神經刺激 (VNS) 市場規模將達到 5.5015 億美元，到 2025 年將成長至 5.9581 億美元，到 2033 年將成長至 11.2755 億美元，在預測期（2026-2033 年）內複合年成長率為 8.3%。

迷走神經刺激（VNS）市場正經歷顯著成長，這主要得益於多種因素的共同作用。其中，人口老化、技術進步以及對VNS作為輔助性治療的需求不斷成長是關鍵促進因素。癲癇和偏頭痛等慢性疾病的快速成長，以及這些領域尚未滿足的醫療需求，進一步推動了市場擴張。神經系統疾病和文明病的日益普遍，以及支持創新研發的研究經費，也是推動市場成長的重要因素。此外，微創手術方式的普及也增強了市場的潛力。儘管受疫情限制措施的影響，近期患者數量有所下降，但VNS在治療癲癇和憂鬱症疾病方面的有效性使其成為重要的治療選擇。

迷走神經刺激市場促進因素

隨著老齡化社會的加劇，神經系統疾病的發生率不斷上升，對迷走神經刺激（VNS）等先進治療方案的需求也顯著成長。老年人罹患此類疾病的風險更高，因此迫切需要有效的干涉措施來改善他們的整體健康和生活品質。這一趨勢凸顯了VNS等創新治療方法的重要性，這些療法為神經系統疾病患者提供了症狀管理和功能改善的有前景的選擇。因此，為了滿足這些不斷變化的醫療需求，迷走神經刺激市場正經歷強勁的成長。

限制迷走神經刺激市場發展的因素

迷走神經刺激市場面臨許多限制因素，其中植入手術和後續設備維護的高昂費用尤為突出。這些費用對患者和醫療系統都構成了巨大的經濟障礙，可能限制了部分潛在受益者獲得該治療方法的機會。由於並非所有患者都能負擔得起必要的手術和後續維護費用，這些費用的經濟影響可能會阻礙迷走神經刺激療法的廣泛應用。這種經濟負擔是影響迷走神經刺激市場整體成長和普及的關鍵因素。

迷走神經刺激（VNS）市場趨勢

受患者對便利、舒適的治療方法需求日益成長的推動，迷走神經刺激（VNS）市場正經歷著向非侵入性解決方案的顯著轉變。這些創新設備透過減少侵入性手術帶來的不適和風險，顯著擴大了潛在用戶群。隨著醫療機構致力於改善患者體驗和治療效果，非侵入性VNS技術正擴大被納入各種神經和精神疾病的治療通訊協定中。這種日益成長的接受度不僅提高了患者的依從性，也推動了市場成長，並為VNS治療創造了一個更包容的環境。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管環境
• 專利分析

全球迷走神經刺激市場規模（依產品類型及複合年成長率分類）（2026-2033 年）

• 植入式迷走神經刺激器
• 外部 VNS 設備

全球迷走神經刺激市場規模（按應用及複合年成長率分類）（2026-2033 年）

• 癲癇
• 憂鬱症
• 偏頭痛
• 其他

全球迷走神經刺激市場規模（按生物材料和複合年成長率分類）（2026-2033 年）

• 金屬
• 陶瓷
• 其他

全球迷走神經刺激市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 專科診所
• 門診手術中心

全球迷走神經刺激市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• LivaNova PLC（UK）
• ElectroCore, Inc.（USA）
• Cyberonics, Inc.（USA）
• Boston Scientific Corporation（USA）
• Medtronic PLC（Ireland）
• NeuroPace, Inc.（USA）
• Aleva Neurotherapeutics SA（Switzerland）
• BioControl Medical（Israel）
• Inspire Medical Systems, Inc.（USA）
• Nervana, LLC（USA）
• ReShape Lifesciences Inc.（USA）
• SetPoint Medical（USA）
• Soterix Medical Inc.（USA）
• tVNS Technologies GmbH（Germany）
• Parasym Ltd.（UK）
• Cerbomed GmbH（Germany）
• MicroTransponder Inc.（USA）
• NeuroSigma, Inc.（USA）
• BioElectronics Corporation（USA）
• Nexstim Plc（Finland）

結論與建議

Vagus Nerve Stimulation Market size was valued at USD 550.15 Million in 2024 and is poised to grow from USD 595.81 Million in 2025 to USD 1127.55 Million by 2033, growing at a CAGR of 8.3% during the forecast period (2026-2033).

The vagus nerve stimulation (VNS) market is experiencing significant growth driven by a combination of influential factors. The increasing elderly population, advancements in technology, and rising demand for VNS as an adjunct therapy are key contributors. The surge in chronic conditions such as epilepsy and migraines, coupled with the unmet medical needs within these areas, further fuels market expansion. The growth is also enhanced by the prevalence of neurological and lifestyle-related disorders, as well as research funding supporting innovative development. Furthermore, a shift towards less invasive surgical options bolsters market potential. The efficacy of VNS in managing conditions like epilepsy and depression positions it as a pivotal therapeutic avenue, despite recent procedural volume challenges related to pandemic restrictions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Vagus Nerve Stimulation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Vagus Nerve Stimulation Market Segments Analysis

Global Vagus Nerve Stimulation Market is segmented by Product Type, Application, Biomaterial, End User and region. Based on Product Type, the market is segmented into Implantable VNS Devices and External VNS Devices. Based on Application, the market is segmented into Epilepsy, Depression, Migraine and Others. Based on Biomaterial, the market is segmented into Metallic, Ceramics and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics and Ambulatory Surgical Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Vagus Nerve Stimulation Market

The increasing prevalence of neurological disorders among the aging population is significantly stimulating the demand for advanced therapeutic solutions such as Vagus Nerve Stimulation (VNS). As older adults face a higher risk of developing these conditions, there is a pressing need for effective interventions that can improve their overall well-being and quality of life. This trend underscores the importance of innovative treatments like VNS, which offer promising alternatives for managing symptoms and enhancing the functional capabilities of individuals suffering from neurological challenges. Consequently, the Vagus Nerve Stimulation market is experiencing robust growth as it responds to these evolving healthcare needs.

Restraints in the Vagus Nerve Stimulation Market

The Vagus Nerve Stimulation market faces significant restraints due to the high costs associated with the implantation procedures and the ongoing maintenance of the devices. These expenses can create substantial financial barriers for both patients and healthcare systems, potentially limiting access to this treatment option for individuals who could benefit from it. The economic implications of these costs may hinder widespread adoption and utilization of VNS therapies, as not all patients can afford the necessary procedures and subsequent upkeep. This financial strain is a critical factor that could impact the growth and acceptance of the Vagus Nerve Stimulation market overall.

Market Trends of the Vagus Nerve Stimulation Market

The Vagus Nerve Stimulation (VNS) market is witnessing a significant trend toward non-invasive solutions, driven by growing consumer demand for accessible and patient-friendly treatment options. These innovative devices present major advantages by mitigating the discomfort and risks associated with invasive procedures, thus broadening the demographic of potential users. As healthcare providers seek to enhance patient experiences and outcomes, non-invasive VNS technologies are becoming increasingly integrated into treatment protocols for various neurological and psychiatric conditions. This rising acceptance not only fosters greater patient compliance but also boosts market growth, establishing a more inclusive landscape for VNS therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Vagus Nerve Stimulation Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Implantable VNS Devices
• External VNS Devices

Global Vagus Nerve Stimulation Market Size by Application & CAGR (2026-2033)

• Market Overview
• Epilepsy
• Depression
• Migraine
• Others

Global Vagus Nerve Stimulation Market Size by Biomaterial & CAGR (2026-2033)

• Market Overview
• Metallic
• Ceramics
• Others

Global Vagus Nerve Stimulation Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

Global Vagus Nerve Stimulation Market Size & CAGR (2026-2033)

• North America (Product Type, Application, Biomaterial, End User)
  • US
  • Canada
• Europe (Product Type, Application, Biomaterial, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Application, Biomaterial, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Application, Biomaterial, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Application, Biomaterial, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• LivaNova PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ElectroCore, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cyberonics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic PLC (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeuroPace, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aleva Neurotherapeutics SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioControl Medical (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inspire Medical Systems, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nervana, LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ReShape Lifesciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SetPoint Medical (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Soterix Medical Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• tVNS Technologies GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parasym Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cerbomed GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroTransponder Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeuroSigma, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioElectronics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nexstim Plc (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations